Cold Agglutinin Disease Drug Hemolysis Newly Approved

Enjaymo to decrease the need for transfusion due to cold agglutinin disease

, ,

Drug Name: Enjaymo

Indications: To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease.

Active Ingredient: Sutimlimab-jome

Company: Bioverativ USA Inc (a Sanofi company)

Approval Date: 2/4/2022

Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf?utm_medium=email&utm_source=govdelivery

Related

Drug Practice Process Professional Research

Elevating Healthcare Conversations through AI-Enabled CI: KAI Conversations

Drug Practice Process Professional Research

Revolutionizing Pharmacovigilance with AI: DrugCard

Drug Practice Procedure Process Professional Research

Solving for Precision Medicine with AI-Enabled Solutions: Tempus